A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Abroad (travel likely)RecruitingPHASE1
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy · Myasthenia Gravis · Multiple Sclerosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Stanford Neuroscience Health Center, Palo Alto, California, United States
Columbia University Irving Medical Center, New York, New York, United States
LDS Hospital - Intermountain Health, Salt Lake City, Utah, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Corner Hawkesbury Road and Darcy Road, Westmead, New South Wales, Australia
Study leads
Kite Study Director
Study Director
Kite, A Gilead Company